From Chicago drug store to global medical giant: the evolution of Abbott Laboratories
In short: Founded in 1888 by a physician seeking better ways to deliver medicine, Abbott Laboratories has transformed from a small Chicago operation into a multinational powerhouse. Today, it dominates the medical device and diagnostics landscape, balancing a massive portfolio of nutritional products, branded generics, and life-saving technology across 160 countries.
Wallace Abbott, a physician and drug store owner, launched the Abbott Alkaloidal Company in 1888. His breakthrough was the creation of dosimetric granules, which provided more consistent dosages of alkaloids like morphine and quinine than the unstable liquid preparations of the era. This focus on precision and reliability set the foundation for a company that would eventually span the globe, moving its headquarters to North Chicago in 1922.
Throughout the 20th and 21st centuries, Abbott expanded aggressively through strategic acquisitions and internal innovation. The company integrated Ross Laboratories in 1964, bringing iconic nutritional brands like Similac and Ensure into its fold. Later, it diversified into high-tech medical devices, including the FreeStyle Libre glucose monitoring system, which was recognized by the Galien Foundation as the best medical technology of the 1970–2020 period. The company also underwent significant structural changes, most notably the 2013 spin-off of its research-based pharmaceutical division, AbbVie.
Today, Abbott operates across four primary segments: medical devices, diagnostics, nutritional products, and established pharmaceuticals. Its recent history is marked by rapid responses to global health challenges, such as the COVID-19 pandemic, where it deployed a suite of rapid testing solutions, including the portable BinaxNOW antigen test. With a presence in over 160 countries and a workforce that continues to innovate in fields ranging from neuromodulation to cardiovascular care, Abbott remains a central player in the global healthcare infrastructure, consistently ranking among the world's most admired companies.
The company's growth strategy remains heavily reliant on mergers and acquisitions, such as the 2017 purchase of St. Jude Medical for $25 billion and the 2025 agreement to acquire Exact Sciences Corp. for approximately $21 billion. While its operations are vast, the firm maintains a focus on branded generics in developing markets and cutting-edge biowearables, ensuring its influence persists across both emerging economies and advanced medical systems.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Abbott Laboratories
To cite this card, link to https://intellectplus.co.uk/app/wealth-abbott-laboratories.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Business stories · More in Wealth & Business · Latest · A–Z · All topics